Hengyu Medical Secures Over RMB 100 Million in Funding to Advance Laser Atherectomy Technology

Investment Circle (ID: pedaily2012) February 21 News: Recently, Horimed Technology Co., Ltd. (hereinafter referred to as "Horimed") announced the completion ofOver 100 Million Yuan in Financing. This round is led byNew Industry Investment, Huatai Zijin, Beiyang海棠 Fund, Jiuan Medical (002432.SZ), and YuanSheng Ventures jointly invested.. Star Bridge Capital served as the exclusive financial advisor. This round of financing will boost research and development, production, and registration, with a particular focus on accelerating the commercialization process of already listed products.

Horimed Technology Co., Ltd. was founded in 2016, focusing on the research of optical and ultrasound medical imaging technology and laser ablation technology. The core experts have been engaged in related fields for nearly 20 years. It has applied for 174 patents, including 106 inventions, and has been granted 37 invention patents.Focus on the independent research, production, and sales of Intravascular Ultrasound (IVUS) equipment and catheters, Optical Coherence Tomography (OCT) equipment and catheters, dual-catheter systems integrating IVUS/OCT in one device, Fractional Flow Reserve (FFR) platforms based on IVUS and OCT, single-source dual-modality OCT-NIRS technology that combines OCT with Near-Infrared Spectroscopy (NIRS), and intravascular laser plaque ablation technology. Master optical, ultrasound, and catheter platform technologies, continuously innovate at a globally leading level based on core technologies, and are committed to providing an integrated pan-vascular solution based on imaging products for medical professionals and patients.

Gao Chao, Investment Director of New Industry InvestmentIn recent years, the precision diagnosis and treatment technology for vascular intervention in China has developed rapidly. Horimed focuses on the research, production, and sales of devices and consumables such as cardiovascular IVUS, OCT, and IVUS/OCT all-in-one machines. It is a leading domestic company possessing both ultrasound and optical technology platforms, which it uses to continuously develop innovative products. The all-in-one machine independently developed by the company features high integration, cost-effectiveness, and diverse application scenarios, and has been increasingly recognized and utilized by more and more medical institutions. In the future, it is hoped that Horimed will empower clinicians by continuously launching more innovative products for precise vascular intervention diagnosis and treatment, along with professional and systematic academic promotion, ultimately benefiting more patients undergoing PCI procedures.

Wang Qi, Investment Director of Huatai ZijinIt was stated that intravascular imaging technology plays an increasingly important guiding role in the interventional treatment of complex and high-risk cardiovascular diseases. A series of technologies, including IVUS and OCT, can bring excellent clinical benefits to patients. After years of research and development, Horimed has overcome numerous challenges and successfully broken the monopoly of foreign intravascular imaging technologies, developing a series of outstanding IVUS/OCT products. The company adheres to the combination of medical and engineering expertise, innovates boldly, and its products have been highly praised in clinical settings. We have great confidence in the company’s team and technology platform, and we are delighted to continue supporting the company’s growth, contributing to the long-term development of China’s medical device industry.

Wang Renda, Investment Director of Beiyang海棠 FundOCT and IVUS are two key technologies in intraluminal imaging. Horimed is an industry-leading innovative enterprise that possesses both technologies and has integrated them into its products. Since the previous investment by Haitang Fund, Horimed has launched new products such as a portable version and dual-catheter all-in-one machines, enhancing convenience for operators, reducing follow-up costs, and expanding multi-scenario applications. The Horimed team seized the opportunity of centralized procurement, enabling the brand to quickly enter hundreds of major hospitals across China. With appropriate strategies and highly efficient execution, it has achieved the fastest growth among Chinese brands, accelerating the process of domestic substitution. Haitang Fund believes that Horimed will continue to expand its leading position in intraluminal imaging in China while exploring cutting-edge laser ablation technology. Haitang Fund remains optimistic about the project and will continue to support innovation and entrepreneurship among alumni from Tianjin University, contributing to the development of Horimed and the advancement of precision cardiovascular care in China.

Gu Leimin, Partner of YuanSheng VenturesIntravascular Imaging Technology: A Key Pillar of Precision Medicine and a Significant Trend in the Future Diagnosis and Treatment of Cardiovascular DiseasesIntravascular imaging technology for cardiovascular applications is a crucial pillar supporting the development of precision medicine, representing an important trend in the future diagnosis and treatment of cardiovascular diseases. As an essential component of precision medicine, cardiovascular intravascular imaging equipment is not only a necessary tool for complex cardiovascular surgeries but also a highly promising multi-billion-dollar market within the global medical industry. With its keen market insight, Oriza Venture Capital has invested in numerous cutting-edge sectors within the cardiovascular field, with particular attention given to intravascular imaging technology. In this domain, Horimed has emerged as a rising star due to its forward-thinking vision and deep technological expertise. The company boasts an advanced R&D platform for intravascular imaging technology, a robust product pipeline, and a uniquely crafted commercialization strategy. Amidst fierce competition in the intravascular imaging space, Horimed's ability to stand out can be attributed not only to the team’s strategic foresight and exceptional execution but also their relentless pursuit of technological innovation and sense of mission. We are deeply honored to collaborate with the team led by Mr. Zhiyong Liu and Dr. Shiyong Zhao. We look forward to jointly advancing the development of more innovative products and accelerating the global promotion of these products, bringing new breakthroughs to precision diagnosis and treatment of cardiovascular diseases worldwide.

Wu Zhipeng, Star Bridge CapitalHorimed has achieved leapfrog growth in sales revenue in recent years, driven by the commercialization of IVUS and OCT products. Its pipeline layout has expanded from diagnostic technology to therapeutic technology, gradually forming an overall solution for vascular interventional imaging. We are honored to serve Horimed in this round of financing. We believe this financing will accelerate the enhancement of Horimed’s R&D, production, and sales capabilities, laying a solid foundation for the company's continued rapid development in the future.